Cancer immunotherapy has a new name generating buzz beyond PD-1 and PD-L1: TIGIT, short for T-cell immunoreceptor with Ig and ITIM domains. Sitting on the surface of activated T cells, natural killer cells, and regulatory T cells, TIGIT locks onto the ligands CD155 and CD112, which tumors use to keep the immune system quiet. Block that handshake, and CD226 signaling on NK and CD8+ T cells switches back on, giving the body a fighting chance against the tumor. No drug in this class has crossed the regulatory finish line yet, but the race is far from over — candidates are working their way through late-stage trials for non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma, endometrial cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma.

The Players Behind the Science: TIGIT Inhibitors Companies Driving the Field Forward

Behind every headline trial sits a familiar cast of pharma heavyweights and nimble biotechs — Roche, Merck, AstraZeneca, iTeos Therapeutics, and Arcus Biosciences among them — each chasing a slightly different angle on the same target. Since TIGIT tends to show up alongside PD-1 on worn-out immune cells, almost nobody is betting on monotherapy; combination regimens pairing TIGIT blockade with existing PD-1/PD-L1 drugs are the dominant strategy, on the theory that hitting two brakes at once wakes the immune system up faster. Trials now span NSCLC, gastric and gastroesophageal junction cancers, biliary tract cancer, and a growing list of other solid tumors. Meanwhile, the science itself is moving past simple antibodies toward bispecific designs that grab both TIGIT and PD-1 in a single molecule, a shift aimed at squeezing out better results with a simpler regimen.

Sizing Up the Opportunity: A Look at TIGIT Inhibitors Market Size Potential

The numbers behind the disease burden explain why so much capital is flowing here. NSCLC alone accounted for about 204,820 new US cases in 2024, and the 7MM — the US, EU4, UK, and Japan combined — logged roughly 150,900 head and neck squamous cell carcinoma diagnoses that same year. Japan tallied close to 121,910 NSCLC cases in 2024, while renal cell carcinoma made up 80% of UK kidney cancer diagnoses, and lung cancer remains Europe's most common malignancy overall. With that scale of unmet need, forecasts spanning 2022 through 2036 point to substantial growth once ongoing Phase III studies mature and, assuming positive results, clear the path toward launch sometime between 2026 and 2036.

Wins, Losses, and What Comes Next in TIGIT-Directed Care

Arcus Biosciences' domvanalimab, a humanized IgG1 antibody, is being pushed through trials like STAR-221, STAR-121, and PACIFIC-8 for NSCLC and upper GI cancers, with October 2025 survival data from the EDGE-Gastric study adding fuel to its combination story. AstraZeneca's rilvegostomig — co-developed with Compugen under a licensing deal refreshed in December 2025 — takes the bispecific route, targeting PD-1 and TIGIT together in studies such as Gastric01 and ARTEMIDE-HCC01, and is even being tested alongside Daiichi Sankyo's antibody-drug conjugate DATROWAY. It hasn't all been smooth sailing, though. Roche's tiragolumab stumbled when SKYSCRAPER-01 missed its overall survival endpoint, and a September 2025 ESMO readout for the drug in hepatocellular carcinoma also fell short on progression-free survival. iTeos Therapeutics pulled the plug on belrestotug after a costly impairment charge, and earlier casualties like etigilimab and AGEN1777 were dropped by their sponsors entirely — a reminder that this checkpoint has proven harder to crack than PD-1 ever was.

Where the TIGIT Inhibitors Treatment Market Goes From Here

None of this has scared the industry away entirely. Domvanalimab and rilvegostomig remain the two names everyone's watching, and either could reshape the immuno-oncology pecking order with a single strong Phase III result. Once a drug does clear approval, reimbursement will become the next hurdle, since health technology assessments differ widely across the US, EU4, UK, and Japan. Looking ahead, researchers are hunting for biomarkers that can better predict who responds, while newer formats — antibody-drug conjugates, bispecifics, even CAR-T approaches aimed at TIGIT — wait in the wings. The next few years of trial data will settle the real question: whether TIGIT becomes immuno-oncology's second act, or a checkpoint that never quite lived up to the hype.

The broader TIGIT Inhibitors Market will likely be defined by that tension — genuine biological promise weighed against a string of high-profile setbacks — as the field decides whether dual checkpoint blockade can finally deliver on its early promise.

Latest Reports Offered by Delveinsight

diabetes market | uterine fibroids market | cardiopulmonary autotransfusion market | cerebral palsy market | cochlear implants market | elastomeric pump market | hairy cell leukemia market | nocturnal enuresis market | peritoneal dialysis equipment market | adenosine deaminase-severe combined immunodeficiency market | ascites market | atrial fibrillation market | bartonellosis market | chronic renal failure market | clinically isolated syndrome cis market | concussions market size | congestive heart failure market | cystic fibrosis market | fap inhibitor market | fetal and neonatal monitoring devices market | fgfr market 

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com